Clinical Data Visualizations at BMS Merge Trial and Real-World Data

Bio-IT World | The probability of success is low in early drug discovery and gets progressively more expensive on the journey to marketing approval by the Food and Drug Administration (FDA). To “fail early and fail often” has thus become the mantra of medicine developers needing to direct resources to the candidates most likely to triumph, says Philip Ross, director of translational bioinformatics data science at Bristol-Myers Squibb (BMS). Only 9.6% of drugs that make it to phase I trials ever get FDA approved.